Clobazam was associated with reported sedation and dizziness in a Sri Lankan epilepsy cohort

A cross-sectional clinic study found clobazam associations with sedation and dizziness in a population where combination antiseizure treatment was common.

The study population

Guruparan and colleagues surveyed 213 adults with epilepsy receiving follow-up at Teaching Hospital Jaffna in Northern Sri Lanka. Participants had taken antiseizure medication for at least three months. About 64.8% received two or more antiseizure medicines.

Clobazam was used by 66 participants, or 31.0%, usually in combination therapy. Clonazepam was used by 25 participants. These exposures occurred within routine epilepsy treatment, making underlying seizure characteristics and co-medication important to interpreting symptoms.

The clobazam associations

Sedation, memory impairment, and dizziness were the most common reported adverse events overall. In adjusted analyses, clobazam was associated with sedation, with an odds ratio of approximately 2.8 and a 95% confidence interval of 1.44–5.54. It was also associated with dizziness, with an odds ratio of 2.6 and a 95% confidence interval of 1.32–5.13.

The paper did not establish that clobazam explained all sedation or dizziness. Other medicines also showed associations, and use of multiple antiseizure agents was associated with adverse events more generally. The odds ratios do not specify the severity of symptoms or a drug concentration at which they occurred.

Reported symptoms are different from measured impairment

Adverse events were obtained through an interviewer-administered questionnaire and patient report. The study did not measure reaction time, driving performance, or concentrations linked to the symptoms. It therefore provides a clinical tolerability signal rather than a forensic impairment threshold.

Cross-sectional data also cannot reliably establish the order of every exposure and symptom. Adjusted analysis addresses selected measured factors, but treatment indication, combinations, and other unmeasured differences can remain relevant.

Limits on generalization

The authors emphasized the single-center design, recall and reporting bias, and limited ability to detect rare events. People with communication difficulties were excluded, which also affects the represented population.

For an individual review, the findings support examining sedation and dizziness alongside the complete epilepsy regimen and symptom timeline. They do not justify attributing a reported symptom to clobazam solely because the medicine appears on a prescription list.

Source paper

Original analysis of the supplied journal article, identified as PMC13126809.